VPC-3033 is an androgen receptor antagonist used for its potent anti-androgenic activity, including displacement of dihydrotestosterone (DHT) from the androgen receptor (IC50: 0.625–2.5 μM), inhibition of androgen receptor transcriptional activity (IC50 = 0.3 μM), induction of androgen receptor degradation, and effective suppression of androgen receptor signaling in Enzalutamide-resistant prostate cancer cells.